BP/G Radio Intellectual Property Podcast

Guest: Abel de la Rosa, Ph.D - Pharmasset, Inc.

The headlines tell it all: Pfizer Buys Wyeth for $68B; Roche Acquires Genentech for $46.8B. Big Pharma companies are buying each other and consolidating. What will be the future of smaller pharma and biotech companies? How will innovative start-up ventures survive? Where will new research and development come from? BP-G Radio explores the answers to these questions and more with our guest, Abel De La Rosa, Ph.D. In this episode, Dr. De La Rosa brings his vast experience and knowledge of business, science and intellectual property to discuss some of the Big Pharma deals and how they will affect the future of the industry. He also discusses the plight of the small innovator companies and how they will fare in these difficult economic times.

Dr. De La Rosa is currently Senior Vice President, Business Development & Scientific Affairs at Pharmasset, Inc. (NASDAQ: VRUS) and has been with them since 2002. Our guest has held both scientific and business positions at several pharma and biotech companies. Most notably, while at Visible Genetics Inc. he was responsible for the development, transfer and improvement of products, including TRUGENE HIV-1 v1.0 Genotyping Test(r) and other sequencing-based assays for HCV and HBV. He is an inventor and author on several U.S. patents and publications relating to molecular diagnostic methods and techniques for infectious diseases and cancer.

And he loves what he does (give a listen - we need this kind of enthusiasm).

Listen Now:

 Standard Podcasts: Play Now | Play in Popup | Download | Embeddable Player | Hits (232)